Gondi S, Kesselheim AS, Rome BN - New England Journal of Medicine
The arrival of generic liraglutide offers a lower-cost option for treating diabetes and obesity, which could help expand access and reduce financial strain on health systems grappling with skyrocketing GLP-1 drug spending. Insurers, clinicians, and patients should consider generic liraglutide, noting its proven effectiveness and safety, even though newer GLP-1 medications are more convenient and effective.
VIEW SOURCE
Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics
Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine
Chen NC, Bullement A, Zemplenyi AT, O'Bryant CL, Kaizer AM, Anderson KE, McQueen RB - PharmacoEconomics Open